Research programme: neurodegenerative disorders therapeutics - Spark Therapeutics

Drug Profile

Research programme: neurodegenerative disorders therapeutics - Spark Therapeutics

Alternative Names: SPK TPP1

Latest Information Update: 14 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Iowa Research Foundation
  • Developer Spark Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuronal ceroid lipofuscinosis
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Huntington's disease; Neurodegenerative disorders; Neuronal ceroid lipofuscinosis

Most Recent Events

  • 14 Oct 2016 Preclinical trials in Huntington's disease in USA (Parenteral) before October 2016 (Spark Therapeutics pipeline, October 2016)
  • 16 Mar 2016 Preclinical trials in Neuronal ceroid lipofuscinosis in USA (Parenteral) (9195357; FDA website, May 2016)
  • 16 Mar 2016 SPK TPP1 - Spark Therapeutics receives Orphan Drug status for Neuronal ceroid lipofuscinosis in USA (9195357; FDA website, May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top